Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa
- Development stage
- Approved
- Lead developer
- Xiamen Tebao Biological Engineering
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Peginterferon alfa is a long-acting formulation of recombinant interferon alfa, created by the covalent attachment of a polyethylene glycol (PEG) moiety to the protein. This pegylation significantly increases the drug's hydrodynamic size and reduces its renal clearance, extending the half-life and allowing for once-weekly subcutaneous administration. Peginterferon alfa exerts its effects by binding to the heterodimeric interferon alpha/beta receptor (IFNAR1 and IFNAR2), which activates the JAK-STAT signaling pathway. This leads to the induction of numerous interferon-stimulated genes (ISGs) that possess potent antiviral, antiproliferative, and immunomodulatory properties. In the context of chronic hepatitis B (CHB), peginterferon alfa is used to induce an immune-mediated clearance of the virus, aiming for HBsAg loss (functional cure). Beijing Ditan Hospital is a leading institution in China investigating optimized treatment strategies, such as adding peginterferon to existing nucleoside analogue (NA) therapy in patients with low-level viremia to further reduce the risk of hepatocellular carcinoma (HCC).
- Brand names
- PegasysPegIntronYPEG
- Other names
- peginterferonpegylated interferon alfapeginterferon alfa-2apeginterferon alfa-2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa.